Market Data
Market Cap₹10,612.31 Cr.
52W High₹1,260.1
Current Price₹1,151.35
52W Low₹769.6
Down from 52W High8.6 %
Face Value₹10
Performance
ROCE19.22 %
ROE19.74 %
EPS (TTM)₹17.02
EPS Prev Qtr₹13.77
EPS Last Year₹13.84
EBITDA Qtr₹173.38 Cr.
Book Value₹338
Financial Health
Debt/Equity0.54
Debt/Profit2.63
Total Assets₹6,927.232 Cr.
Dividend Yield0.43 %
Promoter Holding27.91 %
Earning Power10.5 %
Valuation
Stock P/E17.3
Industry P/E33.81
Price to Book3.41
Price to Sales2.12
Graham Number₹711.09
Key Metrics
Face Value
₹10
About Strides Pharma Science Ltd
Healthcare · Pharmaceuticals
Strides Pharma Science Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹10. Market cap ₹10,612.31 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- The company has a healthy ROCE of 19.22%, indicating efficient use of capital.
- ROE stands at 20.42%, reflecting strong returns generated on shareholders' equity.
- The company maintains a moderate debt-to-equity ratio of 0.54, suggesting a balanced capital structure.
- With a P/E ratio of 18, the stock may be reasonably valued relative to earnings.
Weaknesses
- The dividend yield is low at 0.42%, which may not attract income-focused investors.
- The P/B ratio of 3.55 indicates that the market values the company at a premium over its book value.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.51 | ₹4,41,477.63 Cr | 0.87% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 86.48 | ₹2,53,031.38 Cr | 0.31% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 77.67 | ₹1,85,216.32 Cr | 0.78% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 27.01 | ₹1,20,897.46 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.28 | ₹1,12,201.64 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 99.31 | ₹1,08,698.22 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Dr Reddys Laboratories Ltd | - | 31.6 | ₹1,02,039.12 Cr | 0.65% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Mankind Pharma Ltd | - | 49.29 | ₹1,00,752.43 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Aurobindo Pharma Ltd | - | 26.56 | ₹97,814.24 Cr | 0.24% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.64 | ₹94,274.49 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 36.67 | ₹65,922.11 Cr | 0.11% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 28.65 | ₹61,804.34 Cr | 1.03% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 110.29 | ₹61,113.53 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.22 | ₹56,860.69 Cr | 1.78% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 46.73 | ₹49,091.33 Cr | 1.97% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ipca Laboratories Ltd | - | 36.13 | ₹48,712.48 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 83.03 | ₹47,949.68 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Gland Pharma Ltd | - | 42.26 | ₹47,764.08 Cr | 0.69% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ajanta Pharma Ltd | - | 38.87 | ₹44,109.77 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales | 1,220.83 | 1,194.65 | 1,323.47 | 1,265.41 |
| ↳ QoQ Growth | - | -2.1% | +10.8% | -4.4% |
| Expenses | 1,038.91 | 1,009.32 | 1,137.01 | 1,092.03 |
| Operating Profit | 181.92 | 185.32 | 186.46 | 173.38 |
| OPM % | 14.9% | 15.51% | 14.09% | 13.7% |
| Other Income | 27.14 | 106.86 | 8.13 | 4.89 |
| Interest | 46.13 | 43.38 | 41.58 | 40.56 |
| Depreciation | 49.64 | 50.62 | 53.25 | 56.4 |
| EBITDA | 231.56 | 235.94 | 239.71 | 229.78 |
| EBITDA Margin % | 18.97% | 19.75% | 18.11% | 18.16% |
| Profit Before Tax | 153.12 | 245.48 | 148.05 | 199.62 |
| Tax % | 14.1% | 15.22% | 12.68% | 17.09% |
| Net Profit | 131.52 | 208.12 | 129.28 | 165.49 |
| ↳ QoQ Growth | - | +58.2% | -37.9% | +28.0% |
| EPS | 13.84 | 21.93 | 13.77 | 17.02 |
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 92.16 | 92.173 |
| Reserves | 2459.67 | 3015.392 |
| Borrowings | 1879.63 | 1668.69 |
| Other Liabilities | 1617.27 | 2150.98 |
| Total Liabilities | 6048.73 | 6927.232 |
| Fixed Assets | 891.87 | 2386.507 |
| CWIP | 99.65 | 161.123 |
| Investments | 409.21 | 291.6 |
| Other Assets | 4648 | 4088 |
| Total Assets | 6048.73 | 6927.232 |
Cash Flows
| Mar 2026 | |
|---|---|
| Cash from Operating Activity | 702.519 |
| Cash from Investing Activity | -173.036 |
| Cash from Financing Activity | -453.409 |
| Net Cash Flow | 76.074 |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 27.86% | 27.86% | 27.91% | 27.91% |
| FIIs % | 28.51% | 29.52% | 28.68% | 28.39% |
| DIIs % | 12.99% | 13.02% | 14.44% | 15.41% |
| Public % | 22.44% | 21.42% | 20.78% | 20.42% |
| No. of Shareholders | 91,206 | 85,589 | 86,616 | 94,856 |
Major Shareholders (>1%)
- Pronomz Ventures LlpPromoter and Promoter Group19.62%
- Quant Mutual Fund - Quant Healthcare FundPublic Shareholding5.59%
- Route One Offshore Master Fund, L.p.Public Shareholding5.05%
- Sbi Life Insurance Co. LtdPublic Shareholding4.76%
As of 2026-06-30View all shareholders →